Sukyin A Sit, MD
Obstetrics/Gynecology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 20
- 4 carriers
- Offices
- 5
Offices
5 locations · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
20 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sit’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
20 of 20 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A83550 · Current
Licensed to practise in California · since 2003 · expires 2026-12-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$7,399
Medicare paid this office $7,399 for 12 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Procedures Medicare counted
| Removal of the uterus | 1-10 | None |
Who their Medicare patients are
12 Original Medicare patients in 2024. Average age 75 · Under 65 0% · Women 100% · Health risk score 0.67. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
The office billed $122,956, Medicare allowed $9,334 and paid $7,399; for 25 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 12 | 25 | 75 | 0.67 | $122,956 | $7,399 |
| 2019 | 21 | 27 | 68 | 1.10 | $35,713 | $4,020 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
Medicaid work
$247,742 in 2024
Medicaid paid $247,742 for 4,230 billed services this clinician did in 2024, up to 71 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 465 | $241,544 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 358 | $3,649 |
| Long return visit (40+ min) | 226 | $875 |
| Return visit (30+ min) | 309 | $837 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 25 | $273 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 25 | $271 |
| Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis | 12 | $262 |
| URINE PREGNANCY TEST | 14 | $20 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 13 | $11 |
| Pain severity quantified; no pain present (COA) (ONC) | 204 | $0 |
| Medication list documented in medical record (COA) | 730 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 594 | $0 |
| 2024 | 4,230 | 16 | 71 | $247,742 |
| 2023 | 2,266 | 19 | 107 | $306,906 |
| 2022 | 1,250 | 12 | 56 | $193,285 |
| 2021 | 1,325 | 10 | 65 | $259,429 |
| 2020 | 462 | 4 | 45 | $128,189 |
| 2019 | 621 | 3 | 57 | $150,518 |
| 2018 | 741 | 3 | 61 | $177,924 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 593 | $299,859 |
| Return visit (30+ min) | 442 | $2,085 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 248 | $1,601 |
| Long return visit (40+ min) | 140 | $937 |
| Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis | 26 | $863 |
| Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique | 26 | $377 |
| Short return visit (20+ min) | 37 | $315 |
| Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique | 26 | $231 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 26 | $220 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 26 | $219 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 23 | $146 |
| URINE PREGNANCY TEST | 30 | $25 |
2022
| Clinic visit/encounter, all-inclusive | 385 | $188,411 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 248 | $2,541 |
| Return visit (30+ min) | 253 | $1,962 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 12 | $183 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 12 | $182 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 15 | $7 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 64 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 85 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 18 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 13 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 111 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 34 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 538 | $257,805 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 73 | $599 |
| Return visit (30+ min) | 194 | $489 |
| Short return visit (20+ min) | 30 | $269 |
| Short return visit | 163 | $245 |
| URINE PREGNANCY TEST | 19 | $22 |
| Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM) | 69 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 121 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 104 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 14 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 360 | $127,342 |
| Return visit (30+ min) | 48 | $397 |
| Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only | 33 | $375 |
| Short return visit | 21 | $74 |
2019
| Clinic visit/encounter, all-inclusive | 431 | $148,903 |
| Return visit (30+ min) | 169 | $1,496 |
| Short return visit (20+ min) | 21 | $119 |
2018
| Clinic visit/encounter, all-inclusive | 530 | $176,237 |
| Return visit (30+ min) | 186 | $1,664 |
| Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision | 25 | $23 |
Drugs they prescribed that Part D paid
$97,291
Pharmacies billed $97,291 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
128 generic and 151 brand-name prescriptions · $97,291 in drug cost · 20 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 42 | $44,196 | $1,052 |
| Premarin | 77 | $30,858 | $401 |
| Estradiol | 52 | $4,248 | $82 |
| Oxybutynin Chloride | 20 | $147 | $7 |
| Nitrofurantoin Mono-Macro | 14 | $137 | $10 |
See all 6 drugs
| Myrbetriq | 42 | $44,196 | $1,052 |
| Premarin | 77 | $30,858 | $401 |
| Estradiol | 52 | $4,248 | $82 |
| Oxybutynin Chloride | 20 | $147 | $7 |
| Nitrofurantoin Mono-Macro | 14 | $137 | $10 |
| Ibuprofen | 11 | $37 | $3 |
Year by year
| 2024 | 279 | 97 | None | 54% | $97,291 |
| 2023 | 216 | 76 | None | 41% | $69,459 |
| 2022 | 219 | 69 | None | 25% | $49,036 |
| 2021 | 171 | 56 | None | 18% | $28,591 |
| 2020 | 169 | 58 | 0% (0) | 27% | $38,720 |
| 2019 | 202 | 65 | 0% (0) | 34% | $40,643 |
| 2018 | 190 | 70 | None | 41% | $45,589 |
| 2017 | 188 | 59 | None | 31% | $35,746 |
| 2016 | 142 | 51 | 0% (0) | 38% | $25,107 |
| 2015 | 128 | 40 | 0% (0) | 70% | $26,394 |
| 2014 | 72 | 32 | 0% (0) | 74% | $13,448 |
| 2013 | 47 | 15 | None | 81% | $8,351 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Myrbetriq | 43 | $39,141 | $910 |
| Premarin | 33 | $13,281 | $402 |
| Estradiol | 54 | $11,342 | $210 |
| Oxybutynin Chloride | 26 | $560 | $22 |
| Ibuprofen | 20 | $77 | $4 |
2022: 7 drugs
| Myrbetriq | 23 | $25,479 | $1,108 |
| Estradiol | 53 | $10,131 | $191 |
| Premarin | 25 | $9,890 | $396 |
| Metronidazole | 13 | $636 | $49 |
| Oxybutynin Chloride | 38 | $520 | $14 |
| Fluticasone Propionate | 11 | $120 | $11 |
| Ibuprofen | 11 | $52 | $5 |
2021: 4 drugs
| Estradiol | 38 | $7,418 | $195 |
| Premarin | 18 | $6,755 | $375 |
| Metronidazole | 23 | $1,386 | $60 |
| Oxybutynin Chloride | 34 | $798 | $23 |
2020: 7 drugs
| Myrbetriq | 17 | $15,738 | $926 |
| Premarin | 20 | $7,289 | $364 |
| Estradiol | 36 | $6,156 | $171 |
| Estrace | 17 | $6,067 | $357 |
| Tolterodine Tartrate Er | 12 | $1,348 | $112 |
| Oxybutynin Chloride Er | 16 | $612 | $38 |
| Oxybutynin Chloride | 17 | $284 | $17 |
2019: 6 drugs
| Myrbetriq | 14 | $11,592 | $828 |
| Premarin | 31 | $10,802 | $348 |
| Estradiol | 40 | $7,105 | $178 |
| Estrace | 18 | $6,277 | $349 |
| Oxybutynin Chloride Er | 18 | $531 | $30 |
| Oxybutynin Chloride | 19 | $438 | $23 |
2018: 5 drugs
| Premarin | 42 | $14,327 | $341 |
| Estrace | 28 | $8,938 | $319 |
| Vesicare | 16 | $7,181 | $449 |
| Estradiol | 12 | $2,773 | $231 |
| Polyethylene Glycol 3350 | 29 | $2,531 | $87 |
2017: 4 drugs
| Estrace | 43 | $12,299 | $286 |
| Premarin | 36 | $12,093 | $336 |
| Polyethylene Glycol 3350 | 31 | $2,490 | $80 |
| Estradiol | 11 | $735 | $67 |
2016: 4 drugs
| Premarin | 42 | $12,114 | $288 |
| Estrace | 18 | $4,802 | $267 |
| Polyethylene Glycol 3350 | 12 | $652 | $54 |
| Ibuprofen | 15 | $73 | $5 |
2015: 1 drug
| Premarin | 74 | $18,870 | $255 |
2014: 1 drug
| Premarin | 40 | $8,577 | $214 |
2013: 1 drug
| Premarin | 32 | $5,824 | $182 |
Money from drug and device companies
$145 in 2024
| 2024 | 1 | 1 | None | $145 |
| 2023 | 2 | 3 | None | $372 |
| 2019 | 1 | 1 | None | $100 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Coloplast | Altis | $145 | 1 payment
|
See the published payment
| Coloplast | Meals · 2024-08-16 | Altis | $145 |
See earlier years (2023, 2019)
2023: $372
| Caldera Medical | Desara | $354 | 2 payments
|
| Pfizer | Myfembree | $17 | 1 payment
|
2019: $100
| Boston Scientific | General Female Sui | $100 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1235235870
- Licence
- CA A83550California A83550: Current · expires 2026-12-31
- Trained
- Stanford University School of Medicine, 1992
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A835500
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 751 S Bascom Ave, San Jose, CA, 95128
- NPI first listed
- 2006-09-14
- NPI last updated
- 2019-04-30
This is when the NPI record was last certified, not a medical board exam.